A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation.

ABSTRACT:

Introduction

In patients with a clinical indication for autologous hematopoietic stem cell transplantation (ASCT), sufficient mobilization of CD34⁺ precursor cells into peripheral blood is essential to ensure adequate hematopoietic stem cell (HSC) collection prior to intensive therapy. However, with standard granulocyte-colony stimulating factor (G-CSF)-based mobilization schemes, an important minority of patients fail to mobilize sufficient (e.g., >10/µL) CD34⁺ cell counts into the peripheral blood and are considered as poor mobilizers (PM). Because failure to achieve sufficient CD34⁺ cell mobilization can negatively affect important clinical treatment endpoints, the use of plerixafor (PLX) was approved to increase CD34⁺ mobilization in

SUBMITTER: Bittrich M 

PROVIDER: S-EPMC10712989 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature